WO2008101344A1 - Soluble bioactive lipophilic compounds compositions - Google Patents
Soluble bioactive lipophilic compounds compositions Download PDFInfo
- Publication number
- WO2008101344A1 WO2008101344A1 PCT/CA2008/000336 CA2008000336W WO2008101344A1 WO 2008101344 A1 WO2008101344 A1 WO 2008101344A1 CA 2008000336 W CA2008000336 W CA 2008000336W WO 2008101344 A1 WO2008101344 A1 WO 2008101344A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ionic surfactant
- mixture
- lipophilic
- phase solution
- bioactive compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 179
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 106
- 150000002634 lipophilic molecules Chemical class 0.000 title claims description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 79
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 61
- 239000002537 cosmetic Substances 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 238000010438 heat treatment Methods 0.000 claims abstract description 15
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 14
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 52
- 239000007788 liquid Substances 0.000 claims description 46
- 239000002775 capsule Substances 0.000 claims description 43
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 34
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 31
- 229930003427 Vitamin E Natural products 0.000 claims description 26
- 235000019165 vitamin E Nutrition 0.000 claims description 26
- 239000011709 vitamin E Substances 0.000 claims description 26
- 229940046009 vitamin E Drugs 0.000 claims description 26
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 22
- -1 sterol esters Chemical class 0.000 claims description 22
- 239000001828 Gelatine Substances 0.000 claims description 20
- 229920000159 gelatin Polymers 0.000 claims description 20
- 235000019322 gelatine Nutrition 0.000 claims description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 235000021323 fish oil Nutrition 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 16
- 235000019198 oils Nutrition 0.000 claims description 16
- 239000008601 oleoresin Substances 0.000 claims description 16
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims description 15
- 229930182558 Sterol Natural products 0.000 claims description 15
- 235000003702 sterols Nutrition 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 244000165082 Lavanda vera Species 0.000 claims description 10
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 10
- 235000010676 Ocimum basilicum Nutrition 0.000 claims description 10
- 240000007926 Ocimum gratissimum Species 0.000 claims description 10
- 240000007817 Olea europaea Species 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 239000001102 lavandula vera Substances 0.000 claims description 10
- 235000018219 lavender Nutrition 0.000 claims description 10
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 10
- 150000003432 sterols Chemical class 0.000 claims description 10
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 8
- 229940072106 hydroxystearate Drugs 0.000 claims description 8
- 229960003511 macrogol Drugs 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 230000003020 moisturizing effect Effects 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 7
- TVLSKGDBUQMDPR-UHFFFAOYSA-N 2,3-Dimethoxy-5-methyl-6-(3-methyl-2-buten-1-yl)-1,4-benzenediol Chemical class COC1=C(O)C(C)=C(CC=C(C)C)C(O)=C1OC TVLSKGDBUQMDPR-UHFFFAOYSA-N 0.000 claims description 6
- 235000013734 beta-carotene Nutrition 0.000 claims description 6
- 239000011648 beta-carotene Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 235000021466 carotenoid Nutrition 0.000 claims description 6
- 150000001747 carotenoids Chemical class 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 150000003669 ubiquinones Chemical class 0.000 claims description 6
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 claims description 5
- 235000006667 Aleurites moluccana Nutrition 0.000 claims description 5
- 244000136475 Aleurites moluccana Species 0.000 claims description 5
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 5
- 244000144927 Aloe barbadensis Species 0.000 claims description 5
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 5
- 244000144725 Amygdalus communis Species 0.000 claims description 5
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 5
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 5
- 244000105624 Arachis hypogaea Species 0.000 claims description 5
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 5
- 235000018262 Arachis monticola Nutrition 0.000 claims description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 5
- 235000007689 Borago officinalis Nutrition 0.000 claims description 5
- 240000004355 Borago officinalis Species 0.000 claims description 5
- 240000007436 Cananga odorata Species 0.000 claims description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 5
- 244000020518 Carthamus tinctorius Species 0.000 claims description 5
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 5
- 240000003538 Chamaemelum nobile Species 0.000 claims description 5
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 5
- 244000131522 Citrus pyriformis Species 0.000 claims description 5
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 5
- 244000060011 Cocos nucifera Species 0.000 claims description 5
- 244000301850 Cupressus sempervirens Species 0.000 claims description 5
- 240000004784 Cymbopogon citratus Species 0.000 claims description 5
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims description 5
- 244000166652 Cymbopogon martinii Species 0.000 claims description 5
- 235000002767 Daucus carota Nutrition 0.000 claims description 5
- 244000000626 Daucus carota Species 0.000 claims description 5
- 244000004281 Eucalyptus maculata Species 0.000 claims description 5
- 241000208152 Geranium Species 0.000 claims description 5
- 244000020551 Helianthus annuus Species 0.000 claims description 5
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 5
- 240000007049 Juglans regia Species 0.000 claims description 5
- 235000009496 Juglans regia Nutrition 0.000 claims description 5
- 240000003553 Leptospermum scoparium Species 0.000 claims description 5
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 5
- 241000219925 Oenothera Species 0.000 claims description 5
- 235000004496 Oenothera biennis Nutrition 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 244000025272 Persea americana Species 0.000 claims description 5
- 235000008673 Persea americana Nutrition 0.000 claims description 5
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 5
- 244000018633 Prunus armeniaca Species 0.000 claims description 5
- 241000220317 Rosa Species 0.000 claims description 5
- 235000017304 Ruaghas Nutrition 0.000 claims description 5
- 235000002911 Salvia sclarea Nutrition 0.000 claims description 5
- 244000182022 Salvia sclarea Species 0.000 claims description 5
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 5
- 244000040738 Sesamum orientale Species 0.000 claims description 5
- 235000021307 Triticum Nutrition 0.000 claims description 5
- 229960002916 adapalene Drugs 0.000 claims description 5
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- 235000011399 aloe vera Nutrition 0.000 claims description 5
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 5
- 229960003942 amphotericin b Drugs 0.000 claims description 5
- 229940035674 anesthetics Drugs 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 claims description 5
- 229940011658 asiatic acid Drugs 0.000 claims description 5
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 claims description 5
- 235000013793 astaxanthin Nutrition 0.000 claims description 5
- 239000001168 astaxanthin Substances 0.000 claims description 5
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 5
- 229940022405 astaxanthin Drugs 0.000 claims description 5
- 239000002199 base oil Substances 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 229960004348 candicidin Drugs 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 235000012754 curcumin Nutrition 0.000 claims description 5
- 239000004148 curcumin Substances 0.000 claims description 5
- 229940109262 curcumin Drugs 0.000 claims description 5
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 5
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 235000010382 gamma-tocopherol Nutrition 0.000 claims description 5
- 239000003193 general anesthetic agent Substances 0.000 claims description 5
- 229940087559 grape seed Drugs 0.000 claims description 5
- 229930013686 lignan Natural products 0.000 claims description 5
- 235000009408 lignans Nutrition 0.000 claims description 5
- 150000005692 lignans Chemical class 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 235000012661 lycopene Nutrition 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- 235000014571 nuts Nutrition 0.000 claims description 5
- 229960000988 nystatin Drugs 0.000 claims description 5
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 5
- 239000006014 omega-3 oil Substances 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 235000020232 peanut Nutrition 0.000 claims description 5
- 229940068065 phytosterols Drugs 0.000 claims description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 229930002330 retinoic acid Natural products 0.000 claims description 5
- 235000002020 sage Nutrition 0.000 claims description 5
- 150000003421 squalenes Chemical class 0.000 claims description 5
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- 229960001727 tretinoin Drugs 0.000 claims description 5
- 239000000341 volatile oil Substances 0.000 claims description 5
- 235000020234 walnut Nutrition 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 239000002478 γ-tocopherol Substances 0.000 claims description 5
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 3
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 3
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 claims description 3
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 3
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 3
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 229940074046 glyceryl laurate Drugs 0.000 claims description 3
- 229940068939 glyceryl monolaurate Drugs 0.000 claims description 3
- 229940075529 glyceryl stearate Drugs 0.000 claims description 3
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 3
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003346 palm kernel oil Substances 0.000 claims description 3
- 235000019865 palm kernel oil Nutrition 0.000 claims description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 3
- 239000001593 sorbitan monooleate Substances 0.000 claims description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 3
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 3
- 239000001570 sorbitan monopalmitate Substances 0.000 claims description 3
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims description 3
- 229950011392 sorbitan stearate Drugs 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 3
- 231100000827 tissue damage Toxicity 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 229960004135 idebenone Drugs 0.000 claims description 2
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 239000002459 polyene antibiotic agent Substances 0.000 claims description 2
- 229920002675 Polyoxyl Polymers 0.000 claims 8
- 241000209140 Triticum Species 0.000 claims 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 229930003448 Vitamin K Natural products 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000000378 dietary effect Effects 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 230000000153 supplemental effect Effects 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 235000019168 vitamin K Nutrition 0.000 claims 2
- 239000011712 vitamin K Substances 0.000 claims 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 229940046010 vitamin k Drugs 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000007891 compressed tablet Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008238 pharmaceutical water Substances 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 54
- 235000021302 avocado oil Nutrition 0.000 description 28
- 239000008163 avocado oil Substances 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 26
- 239000012071 phase Substances 0.000 description 22
- 238000004090 dissolution Methods 0.000 description 11
- 235000015872 dietary supplement Nutrition 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000012867 bioactive agent Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000011496 sports drink Nutrition 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000007928 solubilization Effects 0.000 description 6
- 238000005063 solubilization Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 239000005515 coenzyme Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 125000005908 glyceryl ester group Chemical group 0.000 description 2
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 150000001579 beta-carotenes Chemical class 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
- A61Q1/06—Lipsticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/08—Preparations containing skin colorants, e.g. pigments for cheeks, e.g. rouge
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/12—Face or body powders for grooming, adorning or absorbing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/04—Preparations for permanent waving or straightening the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Definitions
- the present invention relates to the solubilization of lipophilic bioactive compounds. More particularly, the invention relates to the solubilization of lipophilic bioactive agents using non-ionic surfactant solubilizers. Even more particularly, the present invention relates to methods for preparing water soluble compositions of lipophilic bioactives.
- bioactive compounds or bioactives important in the food, pharmaceutical and cosmetic industries are lipophilic and, therefore, insoluble in aqueous solutions. These compounds are used in many different forms for many different purposes. For example, bioactive lipophilic compounds used in the cosmetic industry are often applied to the skin in the form of a cream. Similarly, pharmaceutical uses require dosage forms such as oral, topical or intravenous. Food supplements are usually delivered orally in solid or liquid form. It is recognized, therefore, that there is a pressing need to develop new technologies for improving the bioavailability of these insoluble bioactives. It is also important that any technology for increasing the bioavailability of bioactives produces a composition that is amenable to a broad range of applications. Increasing the bioavailability of these bioactives can be achieved by improving their solubility in aqueous solutions.
- Coenzyme Qio (“CoQi 0 ”) is one example of a lipophilic bioactive that is of particular interest as it has applications in the food, cosmetic and pharmaceutical fields.
- CoQio also called ubiquinone, is found naturally in the inner membrane of the mitochondria and is involved in electron transfer in oxidative phosphorylation.
- US Patent 6,300,377 entitled “Coenzyme Q products exhibiting high dissolution qualities” discloses a liquid dosage form of CoQio for oral, cosmetic, dietary supplement or pharmaceutical dosage form.
- the formulation is non-aqueous and comprises CoQi 0 , a polysorbate surfactant, a vegetable oil or triglyceride, a glyceryl ester and optionally a phospholipids such as hydroxylated lecithin or tocopherols to solubilize the CoQi 0 .
- US Patent 6,441,050 entitled “Palatable oral coenzyme Q liquid” discloses a pediatric pharmaceutical liquid dosage form of CoQi 0 that is also pleasant-tasting.
- the formulation is aqueous based and comprises CoQi 0 , with a polysorbate surfactant, a vegetable oil or triglyceride, a glyceryl ester and optionally a phospholipids such as hydroxylated lecithin to enhance the palatability of CoQi 0 , a sweetener and water.
- US Patent 6,740,338 entitled “Reduced form of Coenzyme Q in high bioavailability stable oral dosage form” discloses a formulation for the reduced form of CoQi 0 in combination with a lipid soluble reducing agent effective to maintain the CoQi 0 in a reduced state and preferably encapsulated in a soft gelatine capsule.
- U.S. Patent 6,616,942 entitled “Coenzyme QlO formulation and process methodology for soft gel capsules manufacturing” discloses a method and formulation for improving bioavailability of CoQi 0 by delivering it in a soft get capsules containing CoQi 0 , beta- carotenes, Vitamin E, and medium chain triglycerides in rice bran oil and an optional thickener, such as bee's wax, in a soft gel capsule so that a maximum of the CoQi 0 is absorbed by the human body.
- U.S. patent 6,623,734 entitled “Super absorption coenzyme QlO” also discloses a soft gel capsule method and formulation for delivery of CoQi o with high bioavailability.
- Patent 7,094,804 entitled “Water free ubiquinone concentrate” discloses a water soluble, essentially water-free CoQi 0 concentrate comprising CoQio, a light oil containing triglycerides, and an emulsifier such as polysorbate present in at least about 73 weight % of the total weight of the concentrate. A method for preparing the concentrate is also disclosed.
- U.S. Patent 5,989,583 entitled “Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability” discloses a dry solid lipid composition for use in food additives or dietary supplements that in one form, comprises CoQ 10 , a lipid or mixture of lipids that are solid at room temperature and a phospholipid.
- Nano-sized self-assembled structured liquids discloses nano-sized self-assembled structured concentrates for use as effective carriers for transferring active components into the human body.
- the nano-sized self-assembled concentrates are liquid concentrates and comprise an aqueous phase, an oil phase, a surfactant, a co-solvent and co-surfactant.
- US patents 6,045,826, 6,191,172 and 6,632,443 disclose methods of improving solubility of lipophilic compounds, such as Coenzyme Q 10 , in aqueous media.
- Non-ionic surfactants such as cremophor have been utilized as excipients for injectable pharmaceuticals with mixed results.
- Such surfactants have also been utilized in compositions with neutraceutical compounds in the presence of solvents, particularly for anything greater than small amounts of insoluble compounds such as CoQi 0 (see, e.g., U.S. App. #s 2003/147927, 20040167034, 20060198830, 2007/141090 and PCT App. No. WO 2006/080903, WO 2005/079758 and WO 2007/061752).
- the present invention is a based on the surprising discovery that the solubility and bioavailability of lipophilic bioactive compounds such as CoQi 0 can be greatly improved through the use of non-ionic surfactant solubilizers.
- non-ionic surfactant solubilizers it has been discovered that water soluble and highly bioavailable compositions of CoQi 0 can be easily prepared using commercially available non-ionic surfactant solubilizers.
- the present invention provides compositions having enhanced dissolution and bioavailablity of lipophilic bioactive compounds whereby the bioactive compound is combined with a non-ionic surfactant.
- the present invention provides compositions having enhanced dissolution and bioavailablity of lipophilic bioactive compounds whereby the lipophilic bioactive compound is combined with a non-ionic surfactant having a hydrophilic lipophilic balance of between about 10 and about 20 and wherein the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant is from about 1 :0.5 to about 1 :25.
- the present invention further provides methods for the preparation of lipophilic bioactive compounds having enhanced dissolution and bioavailability whereby the lipophilic bioactive compound is combined with a non-ionic surfactant.
- the present invention provides pharmaceutical, food product or cosmetic formulations of CoQio comprising an effective amount of CoQi 0 in the form of a water-soluble composition and a pharmaceutically or food or cosmetically acceptable additive or additives or vehicle(s).
- the present invention also provides pharmaceutical, food product or cosmetic formulations of lipophilic bioactive compounds comprising an effective amount of the lipophilic bioactive compound in the form of a water-soluble composition and a pharmaceutically or food or cosmetically acceptable additive or additives or vehicles).
- a method of preparing a stable solution including a lipophilic bioactive compound and water comprising the steps of: providing a non-ionic surfactant; preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio; heating the mixture to a temperature necessary to obtain a clear melt; and adding heated water to the mixture to form the stable solution.
- a method of preparing a stable solution including a lipophilic bioactive compound and water comprising the steps of: providing a non-ionic surfactant; preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio; heating the mixture to a temperature necessary to obtain a clear melt; and formulating with or without acceptable additives into solid dosage forms.
- a non- ionic surfactant for preparing a water soluble solution comprising a lipophilic bioactive compound.
- a water soluble pharmaceutical composition comprising a pharmaceutically effective amount of a lipophilic compound and a non-ionic surfactant.
- a water soluble cosmetic composition comprising a cosmetically effective amount of an active lipophilic compound and a non-ionic surfactant.
- a water soluble food composition comprising an effective amount of a bioactive lipophilic compound and a non-ionic surfactant.
- a water soluble hair care composition comprising an effective amount of a bioactive lipophilic compound and a non-ionic surfactant.
- a method of the prophylaxis or treatment of a medical disorder associated with oxidative tissue damages or mitochondrial dysfunctions comprising administering to a human or a warm-blooded animal in need of such prophylaxis or treatment a therapeutically effective amount of a water-soluble composition according to the present invention.
- the lipophilic bioactive compounds of the present invention include all those pharmaceutical and bioactives with bioavailability issues as a result of poor aqueous solubility.
- pharmaceutical actives include: CoQio, ubiquinones, ubiquinols and sterols for various disorders; amphotericin-B, nystatin, and candicidin antibiotics; anticancer drugs such as taxol and doxorubicin; anesthetics such as propafol; and mixtures thereof.
- bioactives for cosmetic and food applications include: ubiquinones, ubiquinols, idebenone, phytosterols, sterols, sterol esters; flavonoids, carotenoids, tocopherols and other phytochemicals, fish oil containing polyunsaturated fatty acids, omega 3 fatty acids, EPA, DHA; carotenoids, such as ⁇ -carotene, astaxanthin, canatxanthin, lycopene; squalenes; gamma-tocopherol; curcumin; lignans; lunastatin; leutin; aloe vera; essential oils, such as tea tree, basil, eucalyptus, cedarwood, cypress, lemon, lavender, sage, lemongrass, evening primrose, chamomile, lavender, geranium, rose, neroli, ylang ylang, clary sage, palmarosa, carrot, basil; carrier oils, such as sunflower, walnut, olive
- the non-ionic surfactant of the present invention is completely miscible with water.
- the surfactant component has a high affinity for and solubility in water, it is bio-compatible (with little to no side effects) and has a melting point close to or below body temperature (about 37 0 C).
- Other characteristics of concern preferably include good taste and odor, clarity, low toxicity, and other factors that will be determined by the application of the compound.
- Various classes of non-ionic surfactants are embraced by the present invention.
- the non-ionic surfactant contains polyethylene glycol (PEG). More specifically, the most preferred PEG-containing surfactant for use in the preparation of the present invention could be defined in several distinct classes.
- a first class of PEG has a poly oxy ethylene moiety and a hydrophobic moiety consisting of saturated or unsaturated alkyl or alkylphenyl groups.
- a second class of PEG-containing surfactants derived from triglyceride oils, which includes polyoxythylated vegetable oils. Other classes of non-ionic surfactants are also within the scope of the present invention.
- the non-ionic surfactant of the present invention is preferably selected from the group consisting Cremophor RH 40TM (polyoxyl 40 hydrogenated castor oil), Cremophor ELTM (polyoxyl 35 castor oil), Cremophor ELPTM (polyoxyl 35 castor oil), and Solutol HS 15TM (macrogol 15 hydroxystearate), PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-60 castor oil, monostearate (and derivatives thereof), glyceryl laurate, glyceryl stearate, glyceryl oleate, glyceryl monooleate, glyceryl monolaurate, sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan stearate, nonyl phenols, octyl phenols, caprylocaproyl polyoxyglycerides, lauroyl polyoxyglycerides
- the non-ionic surfactant is Cremophor RH 40TM (polyoxyl 40 hydrogenated castor oil), Cremophor ELTM (polyoxyl 35 castor oil), Cremophor ELPTM (polyoxyl 35 castor oil), Solutol HS 15TM (macrogol 15 hydroxystearate) or TPGSTM (d- ⁇ -tocopheryl polyethylene glycol succinate).
- Cremophor RH 40TM polyoxyl 40 hydrogenated castor oil
- Cremophor ELTM polyoxyl 35 castor oil
- Cremophor ELPTM polyoxyl 35 castor oil
- Solutol HS 15TM microgol 15 hydroxystearate
- TPGSTM d- ⁇ -tocopheryl polyethylene glycol succinate
- Sustained solubilization ensures that the drug will remain solubilized in the gastrointestinal tract for a significant amount of time and, thus, improve transport across the aqueous boundary layer.
- compositions having enhanced dissolution and bioavailablity of lipophilic bioactive compounds whereby the lipophilic bioactive compound is combined with a non-ionic surfactant having a hydrophilic lipophilic balance of between about 10 and about 20 and wherein the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant is from about 1.0.5 to about 1 :25.
- the invention composition comprises the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant of from about 1 : 1 to about 1 : 10; more preferably from about 1 :3 to about 1 :5.
- the ratio is dependent on the particulate bioactive and is the ratio required to obtain complete solubilization of the bioactive in the non-ionic surfactant as a single- or one-phase solution upon cooling. This ratio results in higher levels of the bioactive compounds in solution than existing technologies, in the range of 10% or greater, more typically 20%, 25%, 33%, 50% or greater of the bioactive compound in relation to the percentage of the surfactant.
- a method of preparing a stable solution including at least one lipophilic bioactive compound and at least one non-ionic surfactant comprising the steps of: providing a non-ionic surfactant and the lipophilic bioactive compound in a predetermined molar ratio, and heating the non-ionic surfactant and the lipophilic bioactive compound to a temperature necessary to obtain a clear melt.
- the lipophilic bioactive compound and the non-ionic surfactant compound can be mixed prior to heating to create the clear melt, or heated separately to each (or in groups) create clear melt solutions.
- the lipophilic bioactive compound(s) and non-ionic compounds can be melted separately, combined in an appropriate ratio and the mixture reheated and mixed until a single phase solution results.
- the melted formulating can occur with or without acceptable additives into solid dosage forms.
- the invention also includes compositions produced by this method.
- the melting point of most compounds are known to those skilled in the art and may depend on factors such as pressure, humidity, and other such factors which trigger melting of compounds.
- the compounds should be heated to such temperature to obtain a clear melt where the components will appear relatively transparent.
- preparation can occur at lower temperatures but be stirred or agitated for longer periods of time.
- the quantity and the preparation temperature the time needed to dissolve the components will vary.
- it can also be prepared by sonication, microwave, or other mixing method that creates a homogenous liquid or single-phase solution.
- Suitable manufacturing equipment would include, for example, stainless steel, heating jacketed, pressurized or non-pressurized, lightening mixers.
- the temperature range for melting the components is preferably from about 20° C and about 120° C, more preferably about 25° C to about95° C, more preferably about 30° C to about 95° C, more preferably about 35° C to about90° C, more preferably about 40° C to about85° C, more preferably about 45° C to about80° C, and most preferably about 50° C to about70°C.
- a substantially clear or clear emulsion is formed.
- the emulsion (of individual components or combinations thereof) stays clear on cooling to room temperature.
- the emulsion does not separate into two layers on cooling to room temperature but remains in a single-phase solution. Sometimes heating to temperatures of 120° C is required (bioactive stability is necessary) but more normally about 50° C to about70° C
- the mixing or agitation step mixes the components and preferably includes magnetic stirring, sonication, shaking and vortex agitation, and includes agitators such as orbital shakers, sonicators, vibrators, and stirrers.
- a liquid solubilized, bioavailable form of a lipophilic bioactive agent which for the purposes of the description of the preferred embodiment is CoQ io
- a suitable non-ionic surfactant as described above
- a gel forms which is stirred vigorously for about an hour and slowly the CoQi 0 goes into solution to form a bright red/orange clear solution at a concentration of 50mg/g.
- Such solution is stable and can then be used to manufacture creams, drinks, solid oral dosage forms and IV dosage forms with or without additional materials such as flavours, buffers, preservatives, binders, fillers etc.
- solubilised, bioavailable CoQio can be prepared by dissolving the bioactive lipophilic compound and the solubilizing agent in a predetermined molar ratio in a water- miscible organic solvent and subsequently diluting the solution with a predetermined amount of water and then removing the organic solvent from the solution and optionally an amount of water necessary to achieve a desired concentration of the water-soluble composition.
- the solvent and water may be removed by any conventional means known to the person skilled in the art including, for example, evaporation under reduced pressure.
- a further alternate method of preparing a water soluble composition of a lipophilic bioactive agent such as CoQ 10 involves first dissolving the lipophilic bioactive agent and the non-ionic surfactant in a water miscible solvent. The next step is to dilute the resulting solution with a predetermined amount of water. The following step is the removal from the solution of the organic solvent and optionally an amount of water necessary to achieve a desired concentration of the water soluble composition.
- the present invention also includes dry formulations of a lipophilic bioactive agent which solubilises in water upon contact.
- dry formulations are prepared by melting for example CoQi 0 and a suitable non-ionic surfactant together by heating a mixture of the two components to around 65° C in order to form a melt. Water may optionally be added at this point to form a gel which is stirred vigorously for about an hour and slowly the CoQio goes into solution to form a bright red/orange clear solution at a concentration of 50mg/g. The water is then removed by lyophilisation or other methods known in the art. Dry formulations may need additional ingredients such as polyethylene glycol 600, polyethylene glycol 400 or polypropylene glycol to stabilize the complex.
- the liquid complex may also be lyophilized and filled into capsules or vials or compressed into tablets with or without additional materials.
- the dry formulation is useful for example in the preparation of oral dosage forms such as tablets and capsules.
- the lipophilic bioactive agent is solubilized upon ingestion where it is readily absorbed.
- compositions required in a sterile format can be preferably subjected to heat or filter sterilization.
- composition of solubilised bioavailable bioactive lipophilic compound of the present invention can be used in the preparation of pharmaceutical dosage forms known in the art including topical, oral, parenteral, suppository and aerosol.
- Routes of administration include intravenous, oral, topical, rectal, parenteral (injectable), local, inhalant and epidural administration.
- the compositions of the invention may also be conjugated to transport molecules or included in transport modalities such as vesicles and micelles to facilitate transport of the molecules.
- the compositions of the invention may also be conjugated to transport molecules, monoclonal antibodies or transport modalities such as vesicles and micelles.
- Pharmaceutical compositions including the compounds of the present invention can be administered to humans or animals.
- compositions of the present invention are also used to prepare cosmetic preparations, including hair care products, known in the art including creams, gels or liquid preparations such as aerosols and mists.
- the cosmetic preparations include foam baths, oil baths, oil moisturizers, sun protection agents, lotions, baby care products, gels or ointments and, oil bodies, emulsifiers, hyperfatting agents, pearl lustre waxes, consistency substances, thickening agents, polymers, silicon compounds, fats, waxes, stabilizing agents, biogenic active substances, deodorants, agents against dandruff, film forming agents, swelling agents, UV light protection factors, antioxidants, inorganic colour pigments, hydrotropes, preservatives, insect repellents, self tanning agents, perfume oils, and colouring agents.
- cosmetics of the present invention also include: skin-care creams, serums, lotions, powders, perfumes, lipsticks, fingernail polishes, eye and facial makeup, permanent waves, hair colors, hair shampoo, hair conditioners, deodorants, bath oils, bubble baths, and many other types of products.
- Cosmetic compositions including the compounds of the present invention can be administered to humans or animals.
- compositions of the present invention are also used to prepare food formulations known in the art including dry solid, wet semi-solid and liquid formulations.
- Foods of the present invention include liquid and solid dietary supplements, liquid and solid nutritional supplements, functional foods, functional drinks, and many other types of products.
- Food compositions including the compounds of the present invention can be administered to humans or animals.
- the composition comprising a non- ionic surfactant and bioactive compound is a nutritional supplement or nutraceutical prepared as a dietary supplement.
- the composition can be prepared in a hard or soft gelatin capsules by means known in the art.
- the composition can also be added to drinks or beverages, or in other palatable solution.
- the non-ionic surfactant will have palatable characteristics or masked with flavoring.
- an effective amount of the solubilized and bioavailable lipophilic bioactive compound is added to the formulation in a therapeutically effective amount along with any additional acceptable additive or vehicle selected from, for example, solvents, adjuvants, sweeteners, fillers, colourants, flavouring agents, lubricants, binders, moisturizing agents, preservatives and mixtures thereof as the case may be.
- any additional acceptable additive or vehicle selected from, for example, solvents, adjuvants, sweeteners, fillers, colourants, flavouring agents, lubricants, binders, moisturizing agents, preservatives and mixtures thereof as the case may be.
- CoQio can be used in the treatment of certain ailments including hypercholesteremia, infectious diseases and cancers.
- a pharmaceutical preparation for use in the treatment of hypercholesterolemia according to the present invention comprises a therapeutically effective amount of solubilised composition CoQio and a pharmaceutically acceptable carrier.
- the present invention includes a pharmaceutical composition for the treatment of a fungal infection comprising a therapeutically effective amount of a solubilised composition of CoQio and a macrolide polyene antibiotic as the bioactive lipophilic compound, in conjunction with a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers are known and understood by person skilled in the art.
- CoQio and other lipophilic bioactive compounds are also useful ingredients in cosmetics, including hair care products, for alleviating a number of skin conditions.
- CoQio and other lipophilic bioactive compounds can also be delivered through food compositions for health and therapeutic benefits.
- the manufacture of the fill formulations of the present invention requires standard mixing and heating equipment known by persons skilled in the art, while conventional emulsion methods require high energy input and shearing during processing.
- the fill formulations of the present invention are also physically stable without recrystallization during storage. Stable shelf life is critical for commercialization.
- Solubility and dissolution are the limiting factors in bioavailability of coenzyme Qi 0 . These factors have been successfully overcome by the present invention. Therefore, the bioavailability of the formulations of the present invention is has higher bioavailability than prior art formulations.
- the principle, methodology and formulations developed in this application are not limited to coenzyme Q 10 . They are also applicable to other poorly water-soluble pharmaceutical active ingredients for improving dissolution and bioavailability.
- Cremophor RH 40 (10Og) is heated to around 60°C until a clear liquid results.
- Fish oil (25g) is heated to around 50 0 C until a clear liquid results.
- Cremophor RH 40 and fish oil are combined in an appropriate ratio and the mixture reheated to around 5O 0 C and mixed until a single phase solution results.
- 5g of the mixture is added to 50Og of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results.
- a solution containing Ig of fish oil in 500 ml of spring water results.
- the fish oil complex can be added to Gatorade, Propel or other sports drink.
- Cremophor RH 40 (10Og) is heated to around 6O 0 C until a clear liquid results.
- Oleo resin 25g is heated to around 6O 0 C until a clearer liquid results.
- Cremophor RH 40 and Oleo resin are combined in an appropriate ratio and the mixture reheated to around 6O 0 C and mixed until a single phase solution results.
- 2.5g of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results.
- a solution containing 500 mg of Oleo resin in 500 ml of water results.
- the oleo resin can be added to Gatorade, Propel or other sports drinks.
- Cremophor RH 40 (10Og) is heated to around 6O 0 C until a clear liquid results.
- avocado oil 25g is heated to around 60 0 C until a clear liquid results.
- Cremophor RH 40 and Oleoresin are combined in an appropriate ratio and the mixture reheated 60 0 C and mixed until a single phase solution results.
- 2.5g of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results.
- a solution containing 500 mg of avocado oil in 500 ml of water results.
- the avocado oil can be added to Gatorade, Propel or other sports drinks.
- Cremophor RH 40 (10Og) is heated to around 60 0 C until a clear liquid results.
- Fish oil 25g is heated to around 5O 0 C until a clear liquid results.
- Cremophor RH 40 and fish oil are combined in an appropriate ratio and the mixture reheated to 50 0 C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 200 mg of water soluble fish oil results.
- the fish oil complex can be encapsulated in a soft gelatine capsule.
- CoQi 0 Preparation of a CoQi 0 capsule. Cremophor RH 40 (75g) is heated up to 120 0 C until a clear liquid results. CoQi 0 (25g) is heated to around 60°C until a clear liquid results. Cremophor RH 40 and CoQi 0 are combined in an appropriate ratio and the mixture reheated up to 12O 0 C and mixed until a single phase solution results. The mixture is allowed to cool to room temperature and the cycle repeated until a stable complex is achieved. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 300 mg of water soluble CoQio results. Alternatively the CoQi 0 complex can be encapsulated in a soft gelatine capsule.
- Vitamin E capsule Preparation of a Vitamin E capsule. Cremophor RH 40 (10Og) is heated to around 6O 0 C until a clear liquid results. Vitamin E (25g) is heated to around 60°C until a clear liquid results. Cremophor RH 40 and vitamin E are combined in an appropriate ratio and the mixture reheated to 60 °C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 200 mg of water soluble vitamin E results. Alternatively the vitamin E complex can be encapsulated in a soft gelatine capsule.
- Cremophor RH 40 (10Og) is heated to around 60°C until a clear liquid results.
- avocado oil 25g is heated to around 60°C until a clear liquid results.
- Cremophor RH 40 and avocado oil are combined in an appropriate ratio and the mixture reheated to 6O 0 C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool.
- a capsule containing 200 mg of water soluble avocado oil results.
- the avocado oil complex can be encapsulated in a soft gelatine capsule.
- Cremophor RH 40 (4Og) is heated to around 60°C until a clear liquid results.
- CoQi 0 (5g) and vitamin E (5g) are mixed and heated to around 60°C until a clear liquid results.
- Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to around 60 0 C and mixed until a single-phase solution results.
- 1Og of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results.
- a solution containing Ig of CoQi 0 and 1 g of vitamin E in 500 ml of spring water results.
- the CoQi 0 /vitamin E complex can be added to Gatorade, Propel or other sports drink.
- CoQi 0 /avocado oil beverage Preparation of a CoQi 0 /avocado oil beverage. Cremophor RH 40 (4Og) is heated to around 60°C until a clear liquid results. CoQio (5g) and avocado oil (5g) are mixed and heated to around 60 0 C until a clear liquid results. Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated 60 0 C and mixed until a single phase solution results. 1Og of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing Ig of CoQi 0 and 1 g of avocado oil in 500 ml of spring water results. Alternatively the CoQi 0 /avocado oil complex can be added to Gatorade, Propel or other sports drink.
- Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to around 6O 0 C and mixed until a single phase solution results. 1Og of the mixture is added to 50Og of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing 750 mg of CoQlO,
- CoQ io /avocado oil complex can be added to Gatorade, Propel or other sports drink.
- Cremophor EL (6Og) is heated to around 60 0 C until a clear liquid results.
- CoQio (5g), avocado oil (5g) and vitamin E (5g) are mixed and heated to around 60 0 C until a clear liquid results.
- Cremophor EL and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to around 60 0 C and mixed until a single phase solution results. 4Og of the mixture is added to 6Og of moisturizing cream to produce a cosmetic cream with 1% of each bioactive.
- Cremophor EL (4Og) is heated to around 60 0 C until a clear liquid results.
- CoQio (4g), avocado oil (8g) and vitamin E (6g) are mixed and heated to around 60 0 C until a clear liquid results.
- Cremophor EL and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to 60 0 C and mixed until a single phase solution results.
- 2Og of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results.
- the solution containing 0.08% CoQio, 0.16% avocado oil and 0.12% vitamin E is filled into a spray bottle to produce an enriched body spray.
- Cremophor RH 40 (4Og) is heated to around 60°C until a clear liquid results.
- CoQi 0 (5g) and vitamin E (5g) are mixed and heated to around 60 0 C until a clear liquid results.
- Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated 60°C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool.
- a capsule containing 100 mg of water soluble CoQi 0 and 100 mg of water soluble vitamin E results.
- the complex can be encapsulated in a soft gelatine capsule.
- Cremophor RH 40 (4Og) is heated to around 60°C until a clear liquid results.
- CoQi 0 (5g) and avocado oil (5g) are mixed and heated to around 60 0 C until a clear liquid results.
- Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated 60 0 C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool.
- a capsule containing 100 mg of water soluble CoQi 0 and 100 mg of water soluble avocado oil results.
- the complex can be encapsulated in a soft gelatine capsule.
- Cremophor RH 40 (6Og) is heated to around 60 0 C until a clear liquid results.
- CoQi 0 (5g), avocado oil (5g) and vitamin E (5g) are mixed and heated to around 6O 0 C until a clear liquid results.
- Cremophor EL and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to 6O 0 C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool.
- a capsule containing 67 mg of water soluble CoQi 0 , 67 mg of water soluble avocado oil amd 67 mg of water soluble vitamin E results.
- the complex can be encapsulated in a soft gelatine capsule.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a method of preparing a stable water soluble solution including a lipophilic bioactive compound such as CoQ10. The method involves providing a non-ionic surfactant; preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio; heating the mixture to a temperature necessary to obtain a clear melt; and adding heated water to the mixture to form the stable solution. The invention includes compositions produced by this method and uses of such compositions. These uses include uses in pharmaceutical, food and cosmetic compositions.
Description
SOLUBLE BIOACTIVE COMPOSITIONS
FIELD OF THE INVENTION
The present invention relates to the solubilization of lipophilic bioactive compounds. More particularly, the invention relates to the solubilization of lipophilic bioactive agents using non-ionic surfactant solubilizers. Even more particularly, the present invention relates to methods for preparing water soluble compositions of lipophilic bioactives.
BACKGROUND OF THE INVENTION
Numerous bioactive compounds or bioactives important in the food, pharmaceutical and cosmetic industries are lipophilic and, therefore, insoluble in aqueous solutions. These compounds are used in many different forms for many different purposes. For example, bioactive lipophilic compounds used in the cosmetic industry are often applied to the skin in the form of a cream. Similarly, pharmaceutical uses require dosage forms such as oral, topical or intravenous. Food supplements are usually delivered orally in solid or liquid form. It is recognized, therefore, that there is a pressing need to develop new technologies for improving the bioavailability of these insoluble bioactives. It is also important that any technology for increasing the bioavailability of bioactives produces a composition that is amenable to a broad range of applications. Increasing the bioavailability of these bioactives can be achieved by improving their solubility in aqueous solutions.
Coenzyme Qio ("CoQi0") is one example of a lipophilic bioactive that is of particular interest as it has applications in the food, cosmetic and pharmaceutical fields. CoQio, also called ubiquinone, is found naturally in the inner membrane of the mitochondria and is involved in electron transfer in oxidative phosphorylation.
Several methods and formulations have been published that describe a variety of approaches to obtaining compositions of CoQi o and other lipophilic bioactives having increased bioavailability. For example, US Patent 6,056,971 entitled "Method for enhancing dissolution properties of relatively insoluble dietary supplements and product
incorporating same" discloses a method for enhancing the dissolution properties of relatively insoluble dietary supplements. Specifically claimed is a method for enhancing the bioavailabilty of CoQi0 from an orally delivered soft gelatine capsule from a uniform, non-aqueous solution produced by mixing a non-ionic surface active agent as a solubilizer with a polyhydric alcohol to form a uniform mixture.
US Patent 6,300,377 entitled "Coenzyme Q products exhibiting high dissolution qualities" discloses a liquid dosage form of CoQio for oral, cosmetic, dietary supplement or pharmaceutical dosage form. The formulation is non-aqueous and comprises CoQi0, a polysorbate surfactant, a vegetable oil or triglyceride, a glyceryl ester and optionally a phospholipids such as hydroxylated lecithin or tocopherols to solubilize the CoQi0.
US Patent 6,441,050 entitled "Palatable oral coenzyme Q liquid" discloses a pediatric pharmaceutical liquid dosage form of CoQi0 that is also pleasant-tasting. The formulation is aqueous based and comprises CoQi0, with a polysorbate surfactant, a vegetable oil or triglyceride, a glyceryl ester and optionally a phospholipids such as hydroxylated lecithin to enhance the palatability of CoQi0, a sweetener and water.
US Patent 6,740,338 entitled "Reduced form of Coenzyme Q in high bioavailability stable oral dosage form" discloses a formulation for the reduced form of CoQi0 in combination with a lipid soluble reducing agent effective to maintain the CoQi0 in a reduced state and preferably encapsulated in a soft gelatine capsule.
U.S. Patent 6,616,942 entitled "Coenzyme QlO formulation and process methodology for soft gel capsules manufacturing" discloses a method and formulation for improving bioavailability of CoQi0 by delivering it in a soft get capsules containing CoQi0, beta- carotenes, Vitamin E, and medium chain triglycerides in rice bran oil and an optional thickener, such as bee's wax, in a soft gel capsule so that a maximum of the CoQi0 is absorbed by the human body. U.S. patent 6,623,734 entitled "Super absorption coenzyme QlO" also discloses a soft gel capsule method and formulation for delivery of CoQi o with high bioavailability.
U.S. Patent 7,094,804 entitled "Water free ubiquinone concentrate" discloses a water soluble, essentially water-free CoQi0 concentrate comprising CoQio, a light oil containing triglycerides, and an emulsifier such as polysorbate present in at least about 73 weight % of the total weight of the concentrate. A method for preparing the concentrate is also disclosed.
U.S. Patent 5,989,583 entitled "Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability" discloses a dry solid lipid composition for use in food additives or dietary supplements that in one form, comprises CoQ10, a lipid or mixture of lipids that are solid at room temperature and a phospholipid.
U.S. Patent application 20030232095 entitled "Nano-sized self-assembled structured liquids" discloses nano-sized self-assembled structured concentrates for use as effective carriers for transferring active components into the human body. The nano-sized self- assembled concentrates are liquid concentrates and comprise an aqueous phase, an oil phase, a surfactant, a co-solvent and co-surfactant.
US patents 6,045,826, 6,191,172 and 6,632,443 disclose methods of improving solubility of lipophilic compounds, such as Coenzyme Q10, in aqueous media.
Non-ionic surfactants such as cremophor have been utilized as excipients for injectable pharmaceuticals with mixed results. Such surfactants have also been utilized in compositions with neutraceutical compounds in the presence of solvents, particularly for anything greater than small amounts of insoluble compounds such as CoQi0 (see, e.g., U.S. App. #s 2003/147927, 20040167034, 20060198830, 2007/141090 and PCT App. No. WO 2006/080903, WO 2005/079758 and WO 2007/061752).
Having regard to the above described prior art, there is a need to improve the solubility and bioavailability of lipophilic bioactive compounds such as CoQio-
SUMMARY OF THE INVENTION
The present invention is a based on the surprising discovery that the solubility and bioavailability of lipophilic bioactive compounds such as CoQi0 can be greatly improved through the use of non-ionic surfactant solubilizers. In particular, it has been discovered that water soluble and highly bioavailable compositions of CoQi0 can be easily prepared using commercially available non-ionic surfactant solubilizers.
The present invention provides compositions having enhanced dissolution and bioavailablity of lipophilic bioactive compounds whereby the bioactive compound is combined with a non-ionic surfactant.
More particularly, the present invention provides compositions having enhanced dissolution and bioavailablity of lipophilic bioactive compounds whereby the lipophilic bioactive compound is combined with a non-ionic surfactant having a hydrophilic lipophilic balance of between about 10 and about 20 and wherein the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant is from about 1 :0.5 to about 1 :25.
The present invention further provides methods for the preparation of lipophilic bioactive compounds having enhanced dissolution and bioavailability whereby the lipophilic bioactive compound is combined with a non-ionic surfactant.
The present invention provides pharmaceutical, food product or cosmetic formulations of CoQio comprising an effective amount of CoQi0 in the form of a water-soluble composition and a pharmaceutically or food or cosmetically acceptable additive or additives or vehicle(s).
The present invention also provides pharmaceutical, food product or cosmetic formulations of lipophilic bioactive compounds comprising an effective amount of the lipophilic bioactive compound in the form of a water-soluble composition and a pharmaceutically or food or cosmetically acceptable additive or additives or vehicles).
According to one aspect of the present invention, there is provided a method of preparing a stable solution including a lipophilic bioactive compound and water comprising the steps of: providing a non-ionic surfactant; preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio; heating the mixture to a temperature necessary to obtain a clear melt; and adding heated water to the mixture to form the stable solution.
According to another aspect of the present invention, there is provided a method of preparing a stable solution including a lipophilic bioactive compound and water comprising the steps of: providing a non-ionic surfactant; preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio; heating the mixture to a temperature necessary to obtain a clear melt; and formulating with or without acceptable additives into solid dosage forms.
According to another aspect of the present invention, there is provided a use of a non- ionic surfactant for preparing a water soluble solution comprising a lipophilic bioactive compound.
According to yet another aspect of the present invention, there is provided a water soluble pharmaceutical composition comprising a pharmaceutically effective amount of a lipophilic compound and a non-ionic surfactant.
According to another aspect of the present invention, there is provided a water soluble cosmetic composition comprising a cosmetically effective amount of an active lipophilic compound and a non-ionic surfactant.
According to yet another aspect of the present invention, there is provided a water soluble food composition comprising an effective amount of a bioactive lipophilic compound and a non-ionic surfactant.
According to another aspect of the present invention, there is provided a water soluble hair care composition comprising an effective amount of a bioactive lipophilic compound and a non-ionic surfactant.
According to yet another aspect of the present invention, there is provided method of the prophylaxis or treatment of a medical disorder associated with oxidative tissue damages or mitochondrial dysfunctions, said method comprising administering to a human or a warm-blooded animal in need of such prophylaxis or treatment a therapeutically effective amount of a water-soluble composition according to the present invention.
DETAILED DESCRIPTION OF THE INVENTION Large proportions of compounds, particularly pharmaceutical and nutraceutical compounds, have poor water solubility. The lipophilic bioactive compounds of the present invention include all those pharmaceutical and bioactives with bioavailability issues as a result of poor aqueous solubility. Examples of pharmaceutical actives include: CoQio, ubiquinones, ubiquinols and sterols for various disorders; amphotericin-B, nystatin, and candicidin antibiotics; anticancer drugs such as taxol and doxorubicin; anesthetics such as propafol; and mixtures thereof. Examples of bioactives for cosmetic and food applications include: ubiquinones, ubiquinols, idebenone, phytosterols, sterols, sterol esters; flavonoids, carotenoids, tocopherols and other phytochemicals, fish oil containing polyunsaturated fatty acids, omega 3 fatty acids, EPA, DHA; carotenoids, such as β-carotene, astaxanthin, canatxanthin, lycopene; squalenes; gamma-tocopherol; curcumin; lignans; lunastatin; leutin; aloe vera; essential oils, such as tea tree, basil, eucalyptus, cedarwood, cypress, lemon, lavender, sage, lemongrass, evening primrose, chamomile, lavender, geranium, rose, neroli, ylang ylang, clary sage, palmarosa, carrot, basil; carrier oils, such as sunflower, walnut, olive, sweet almond, apricot kernel, avocado, borage, caster, coconut, emu, grapeseed, jojaba, kukui, nut, olive, peanut, sesame, safflower, wheat germ; oleoresin; retinoic acid; adapalene; azelaic acid; asiatic acid; fatty acids; polyenoic fatty acids; and mixtures thereof.
The non-ionic surfactant of the present invention is completely miscible with water. Preferably, the surfactant component has a high affinity for and solubility in water, it is bio-compatible (with little to no side effects) and has a melting point close to or below body temperature (about 370C). Other characteristics of concern preferably include good taste and odor, clarity, low toxicity, and other factors that will be determined by the application of the compound. Various classes of non-ionic surfactants are embraced by the present invention. Preferably, the non-ionic surfactant contains polyethylene glycol (PEG). More specifically, the most preferred PEG-containing surfactant for use in the preparation of the present invention could be defined in several distinct classes. A first class of PEG has a poly oxy ethylene moiety and a hydrophobic moiety consisting of saturated or unsaturated alkyl or alkylphenyl groups. A second class of PEG-containing surfactants derived from triglyceride oils, which includes polyoxythylated vegetable oils. Other classes of non-ionic surfactants are also within the scope of the present invention.
The non-ionic surfactant of the present invention is preferably selected from the group consisting Cremophor RH 40™ (polyoxyl 40 hydrogenated castor oil), Cremophor EL™ (polyoxyl 35 castor oil), Cremophor ELP™ (polyoxyl 35 castor oil), and Solutol HS 15™ (macrogol 15 hydroxystearate), PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-60 castor oil, monostearate (and derivatives thereof), glyceryl laurate, glyceryl stearate, glyceryl oleate, glyceryl monooleate, glyceryl monolaurate, sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan stearate, nonyl phenols, octyl phenols, caprylocaproyl polyoxyglycerides, lauroyl polyoxyglycerides, stearoyl polyoxylglycerdes and d-α-tocopheryl polyethylene glycol succinate, or combinations thereof. More preferably, the non-ionic surfactant is Cremophor RH 40™ (polyoxyl 40 hydrogenated castor oil), Cremophor EL™ (polyoxyl 35 castor oil), Cremophor ELP™ (polyoxyl 35 castor oil), Solutol HS 15™ (macrogol 15 hydroxystearate) or TPGS™ (d- α-tocopheryl polyethylene glycol succinate). Most prefeiably, the non-ionic surfactant is Cremophor RH 40™ (polyoxyl 40 hydrogenated castor oil), Cremophor EL™ (polyoxyl 35 castor oil) or Cremophor ELP™ (polyoxyl 35 castor oil).
Without limiting the scope of the invention and being bound by theory, it is believed that a number of factors result in the improved dissolution and bioavailability of the present invention. First, mixing the lipophilic bioactive compound with the non-ionic surfactant spontaneously forms micelles including nano-micelles when in contact with water. The formation of nano-micelles improves transient solubilization which improves drug dissolution rates and bioavilability. Second, complex formation of the lipophilic bioactive agent with the non-ionic surfactant improves sustained solubilization. For many poorly water-soluble drugs, transport across the aqueous boundary layer represents the dominant rate-limiting step for drug absorption. Sustained solubilization ensures that the drug will remain solubilized in the gastrointestinal tract for a significant amount of time and, thus, improve transport across the aqueous boundary layer. Finally, reports in the literature demonstrate that surfactants inhibit the Pgp efflux mechanism thereby enhancing absorption of the bioactive.
In a particular embodiment of the present invention, there are provided compositions having enhanced dissolution and bioavailablity of lipophilic bioactive compounds whereby the lipophilic bioactive compound is combined with a non-ionic surfactant having a hydrophilic lipophilic balance of between about 10 and about 20 and wherein the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant is from about 1.0.5 to about 1 :25. Preferably, the invention composition comprises the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant of from about 1 : 1 to about 1 : 10; more preferably from about 1 :3 to about 1 :5. The ratio is dependent on the particulate bioactive and is the ratio required to obtain complete solubilization of the bioactive in the non-ionic surfactant as a single- or one-phase solution upon cooling. This ratio results in higher levels of the bioactive compounds in solution than existing technologies, in the range of 10% or greater, more typically 20%, 25%, 33%, 50% or greater of the bioactive compound in relation to the percentage of the surfactant.
According to one aspect of the present invention, there is provided a method of preparing a stable solution including at least one lipophilic bioactive compound and at least one
non-ionic surfactant, comprising the steps of: providing a non-ionic surfactant and the lipophilic bioactive compound in a predetermined molar ratio, and heating the non-ionic surfactant and the lipophilic bioactive compound to a temperature necessary to obtain a clear melt. The lipophilic bioactive compound and the non-ionic surfactant compound can be mixed prior to heating to create the clear melt, or heated separately to each (or in groups) create clear melt solutions. Alternatively, and preferably in certain circumstances and formulations, the lipophilic bioactive compound(s) and non-ionic compounds can be melted separately, combined in an appropriate ratio and the mixture reheated and mixed until a single phase solution results. The melted formulating can occur with or without acceptable additives into solid dosage forms. The invention also includes compositions produced by this method.
The melting point of most compounds are known to those skilled in the art and may depend on factors such as pressure, humidity, and other such factors which trigger melting of compounds. However, in general, the compounds should be heated to such temperature to obtain a clear melt where the components will appear relatively transparent. Alternatively, preparation can occur at lower temperatures but be stirred or agitated for longer periods of time. Depending upon the type of surfactant and bioactive compound, the quantity and the preparation temperature, the time needed to dissolve the components will vary. In addition to heating, it can also be prepared by sonication, microwave, or other mixing method that creates a homogenous liquid or single-phase solution. Suitable manufacturing equipment would include, for example, stainless steel, heating jacketed, pressurized or non-pressurized, lightening mixers.
The temperature range for melting the components is preferably from about 20° C and about 120° C, more preferably about 25° C to about95° C, more preferably about 30° C to about 95° C, more preferably about 35° C to about90° C, more preferably about 40° C to about85° C, more preferably about 45° C to about80° C, and most preferably about 50° C to about70°C. A substantially clear or clear emulsion is formed. The emulsion (of individual components or combinations thereof) stays clear on cooling to room
temperature. The emulsion does not separate into two layers on cooling to room temperature but remains in a single-phase solution. Sometimes heating to temperatures of 120° C is required (bioactive stability is necessary) but more normally about 50° C to about70° C
The mixing or agitation step mixes the components and preferably includes magnetic stirring, sonication, shaking and vortex agitation, and includes agitators such as orbital shakers, sonicators, vibrators, and stirrers.
In a particular embodiment of the present invention, a liquid solubilized, bioavailable form of a lipophilic bioactive agent, which for the purposes of the description of the preferred embodiment is CoQ io, according to the present invention may be manufactured by melting CoQi o and a suitable non-ionic surfactant (as described above) together by heating a mixture of the two components to around 65° C. The required amount of water is heated separately to 65° C and slowly added to the melt. A gel forms which is stirred vigorously for about an hour and slowly the CoQi0 goes into solution to form a bright red/orange clear solution at a concentration of 50mg/g. Such solution is stable and can then be used to manufacture creams, drinks, solid oral dosage forms and IV dosage forms with or without additional materials such as flavours, buffers, preservatives, binders, fillers etc.
In another particular embodiment of the present invention, solubilised, bioavailable CoQio according to the present invention can be prepared by dissolving the bioactive lipophilic compound and the solubilizing agent in a predetermined molar ratio in a water- miscible organic solvent and subsequently diluting the solution with a predetermined amount of water and then removing the organic solvent from the solution and optionally an amount of water necessary to achieve a desired concentration of the water-soluble composition. The solvent and water may be removed by any conventional means known to the person skilled in the art including, for example, evaporation under reduced pressure.
A further alternate method of preparing a water soluble composition of a lipophilic bioactive agent such as CoQ10 involves first dissolving the lipophilic bioactive agent and the non-ionic surfactant in a water miscible solvent. The next step is to dilute the resulting solution with a predetermined amount of water. The following step is the removal from the solution of the organic solvent and optionally an amount of water necessary to achieve a desired concentration of the water soluble composition.
The present invention also includes dry formulations of a lipophilic bioactive agent which solubilises in water upon contact. Such dry formulations are prepared by melting for example CoQi0 and a suitable non-ionic surfactant together by heating a mixture of the two components to around 65° C in order to form a melt. Water may optionally be added at this point to form a gel which is stirred vigorously for about an hour and slowly the CoQio goes into solution to form a bright red/orange clear solution at a concentration of 50mg/g. The water is then removed by lyophilisation or other methods known in the art. Dry formulations may need additional ingredients such as polyethylene glycol 600, polyethylene glycol 400 or polypropylene glycol to stabilize the complex. They can be filled into hard or soft gelatin capsules or mixing with traditional standard tableting excipients and compressed into tablets. The liquid complex may also be lyophilized and filled into capsules or vials or compressed into tablets with or without additional materials. The dry formulation is useful for example in the preparation of oral dosage forms such as tablets and capsules. The lipophilic bioactive agent is solubilized upon ingestion where it is readily absorbed.
Pharmaceutical formulations required in a sterile format can be preferably subjected to heat or filter sterilization.
The composition of solubilised bioavailable bioactive lipophilic compound of the present invention, and in particular CoQi0, can be used in the preparation of pharmaceutical dosage forms known in the art including topical, oral, parenteral, suppository and aerosol. Routes of administration include intravenous, oral, topical, rectal, parenteral (injectable), local, inhalant and epidural administration. The compositions of the invention may also
be conjugated to transport molecules or included in transport modalities such as vesicles and micelles to facilitate transport of the molecules. The compositions of the invention may also be conjugated to transport molecules, monoclonal antibodies or transport modalities such as vesicles and micelles. Pharmaceutical compositions including the compounds of the present invention can be administered to humans or animals.
The compositions of the present invention are also used to prepare cosmetic preparations, including hair care products, known in the art including creams, gels or liquid preparations such as aerosols and mists. In addition, the cosmetic preparations include foam baths, oil baths, oil moisturizers, sun protection agents, lotions, baby care products, gels or ointments and, oil bodies, emulsifiers, hyperfatting agents, pearl lustre waxes, consistency substances, thickening agents, polymers, silicon compounds, fats, waxes, stabilizing agents, biogenic active substances, deodorants, agents against dandruff, film forming agents, swelling agents, UV light protection factors, antioxidants, inorganic colour pigments, hydrotropes, preservatives, insect repellents, self tanning agents, perfume oils, and colouring agents. A person skilled in the art will appreciate that cosmetics of the present invention also include: skin-care creams, serums, lotions, powders, perfumes, lipsticks, fingernail polishes, eye and facial makeup, permanent waves, hair colors, hair shampoo, hair conditioners, deodorants, bath oils, bubble baths, and many other types of products. Cosmetic compositions including the compounds of the present invention can be administered to humans or animals.
The compositions of the present invention are also used to prepare food formulations known in the art including dry solid, wet semi-solid and liquid formulations. Foods of the present invention include liquid and solid dietary supplements, liquid and solid nutritional supplements, functional foods, functional drinks, and many other types of products. Food compositions including the compounds of the present invention can be administered to humans or animals.
In a particular embodiment of the present invention, the composition comprising a non- ionic surfactant and bioactive compound is a nutritional supplement or nutraceutical
prepared as a dietary supplement. For example, the composition can be prepared in a hard or soft gelatin capsules by means known in the art. The composition can also be added to drinks or beverages, or in other palatable solution. Preferably, the non-ionic surfactant will have palatable characteristics or masked with flavoring.
In each case, an effective amount of the solubilized and bioavailable lipophilic bioactive compound is added to the formulation in a therapeutically effective amount along with any additional acceptable additive or vehicle selected from, for example, solvents, adjuvants, sweeteners, fillers, colourants, flavouring agents, lubricants, binders, moisturizing agents, preservatives and mixtures thereof as the case may be.
CoQio can be used in the treatment of certain ailments including hypercholesteremia, infectious diseases and cancers. For example, a pharmaceutical preparation for use in the treatment of hypercholesterolemia according to the present invention comprises a therapeutically effective amount of solubilised composition CoQio and a pharmaceutically acceptable carrier. Similarly, the present invention includes a pharmaceutical composition for the treatment of a fungal infection comprising a therapeutically effective amount of a solubilised composition of CoQio and a macrolide polyene antibiotic as the bioactive lipophilic compound, in conjunction with a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are known and understood by person skilled in the art.
CoQio and other lipophilic bioactive compounds are also useful ingredients in cosmetics, including hair care products, for alleviating a number of skin conditions.
CoQio and other lipophilic bioactive compounds can also be delivered through food compositions for health and therapeutic benefits.
The manufacture of the fill formulations of the present invention requires standard mixing and heating equipment known by persons skilled in the art, while conventional emulsion methods require high energy input and shearing during processing. The fill formulations
of the present invention are also physically stable without recrystallization during storage. Stable shelf life is critical for commercialization.
Solubility and dissolution are the limiting factors in bioavailability of coenzyme Qi0. These factors have been successfully overcome by the present invention. Therefore, the bioavailability of the formulations of the present invention is has higher bioavailability than prior art formulations. The principle, methodology and formulations developed in this application are not limited to coenzyme Q10. They are also applicable to other poorly water-soluble pharmaceutical active ingredients for improving dissolution and bioavailability.
EXAMPLE 1
Preparation of a fish oil beverage. Cremophor RH 40 (10Og) is heated to around 60°C until a clear liquid results. Fish oil (25g) is heated to around 500C until a clear liquid results. Cremophor RH 40 and fish oil are combined in an appropriate ratio and the mixture reheated to around 5O0C and mixed until a single phase solution results. 5g of the mixture is added to 50Og of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing Ig of fish oil in 500 ml of spring water results. Alternatively the fish oil complex can be added to Gatorade, Propel or other sports drink.
EXAMPLE 2
Preparation of a CoQi0 beverage. Cremophor RH 40 (10Og) is heated to around 6O0C until a clear liquid results. CoQi0 (25g) is heated to around 6O0C until a clear liquid results. Cremophor RH 40 and CoQi0 are combined in an appropriate ratio and the mixture reheated 600C and mixed until a single phase solution results. 2.5g of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing 500 mg of CoQio in 500 ml of water results. Alternatively the CoQio can be added to beer, Gatorade, Propel or other sports drinks or beverage.
EXAMPLE 3
Preparation of an Oleo resin beverage. Cremophor RH 40 (10Og) is heated to around 6O0C until a clear liquid results. Oleo resin (25g) is heated to around 6O0C until a clearer liquid results. Cremophor RH 40 and Oleo resin are combined in an appropriate ratio and the mixture reheated to around 6O0C and mixed until a single phase solution results. 2.5g of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing 500 mg of Oleo resin in 500 ml of water results. Alternatively the oleo resin can be added to Gatorade, Propel or other sports drinks.
EXAMPLE 4
Preparation of an avocado oil beverage. Cremophor RH 40 (10Og) is heated to around 6O0C until a clear liquid results. Avocado oil (25g) is heated to around 600C until a clear liquid results. Cremophor RH 40 and Oleoresin are combined in an appropriate ratio and the mixture reheated 600C and mixed until a single phase solution results. 2.5g of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing 500 mg of avocado oil in 500 ml of water results. Alternatively the avocado oil can be added to Gatorade, Propel or other sports drinks.
EXAMPLE 5
Preparation of a fish oil capsule. Cremophor RH 40 (10Og) is heated to around 600C until a clear liquid results. Fish oil (25g) is heated to around 5O0C until a clear liquid results. Cremophor RH 40 and fish oil are combined in an appropriate ratio and the mixture reheated to 500C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 200 mg of water soluble fish oil results. Alternatively the fish oil complex can be encapsulated in a soft gelatine capsule.
EXAMPLE 6
Preparation of a CoQi0 capsule. Cremophor RH 40 (75g) is heated up to 1200C until a clear liquid results. CoQi0 (25g) is heated to around 60°C until a clear liquid results. Cremophor RH 40 and CoQi0 are combined in an appropriate ratio and the mixture reheated up to 12O0C and mixed until a single phase solution results. The mixture is allowed to cool to room temperature and the cycle repeated until a stable complex is achieved. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 300 mg of water soluble CoQio results. Alternatively the CoQi0 complex can be encapsulated in a soft gelatine capsule.
EXAMPLE 7
Preparation of a Vitamin E capsule. Cremophor RH 40 (10Og) is heated to around 6O0C until a clear liquid results. Vitamin E (25g) is heated to around 60°C until a clear liquid results. Cremophor RH 40 and vitamin E are combined in an appropriate ratio and the mixture reheated to 60 °C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 200 mg of water soluble vitamin E results. Alternatively the vitamin E complex can be encapsulated in a soft gelatine capsule.
EXAMPLE 8
Preparation of a Oleo resin capsule. Cremophor RH 40 (10Og) is heated to around 6O0C until a clear liquid results. Oleo resin (25g) is heated to around 600C until a clear liquid results. Cremophor RH 40 and Oleo resin are combined in an appropriate ratio and the mixture reheated to 600C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 200 mg of water soluble Oleo resin results. Alternatively the Oleo resin complex can be encapsulated in a soft gelatine capsule.
EXAMPLE 9
Preparation of a avocado oil capsule. Cremophor RH 40 (10Og) is heated to around 60°C until a clear liquid results. Avocado oil (25g) is heated to around 60°C until a clear liquid results. Cremophor RH 40 and avocado oil are combined in an appropriate ratio and the mixture reheated to 6O0C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 200 mg of water soluble avocado oil results. Alternatively the avocado oil complex can be encapsulated in a soft gelatine capsule.
EXAMPLE 10
Preparation of a CoQio /Vitamin E beverage. Cremophor RH 40 (4Og) is heated to around 60°C until a clear liquid results. CoQi0 (5g) and vitamin E (5g) are mixed and heated to around 60°C until a clear liquid results. Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to around 600C and mixed until a single-phase solution results. 1Og of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing Ig of CoQi0 and 1 g of vitamin E in 500 ml of spring water results. Alternatively the CoQi0 /vitamin E complex can be added to Gatorade, Propel or other sports drink.
EXAMPLE 11
Preparation of a CoQi0 /avocado oil beverage. Cremophor RH 40 (4Og) is heated to around 60°C until a clear liquid results. CoQio (5g) and avocado oil (5g) are mixed and heated to around 600C until a clear liquid results. Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated 600C and mixed until a single phase solution results. 1Og of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing Ig of CoQi0 and 1 g of avocado oil in 500 ml of spring water
results. Alternatively the CoQi0 /avocado oil complex can be added to Gatorade, Propel or other sports drink.
EXAMPLE 12
Preparation of a CoQi0 /avocado oil/vitamin E beverage. Cremophor RH 40 (6Og) is heated to around 6O0C until a clear liquid results. CoQi0 (5g), avocado oil (5g) and vitamin E (5g) are mixed and heated to around 600C until a clear liquid results.
Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to around 6O0C and mixed until a single phase solution results. 1Og of the mixture is added to 50Og of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. A solution containing 750 mg of CoQlO,
750 mg of avocado oil and 750 mg of vitamin E in 500 ml of spring water results.
Alternatively the CoQ io /avocado oil complex can be added to Gatorade, Propel or other sports drink.
EXAMPLE 13
Preparation of a CoQi0 /avocado oil/vitamin E moisturizing cream. Cremophor EL (6Og) is heated to around 600C until a clear liquid results. CoQio (5g), avocado oil (5g) and vitamin E (5g) are mixed and heated to around 600C until a clear liquid results. Cremophor EL and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to around 600C and mixed until a single phase solution results. 4Og of the mixture is added to 6Og of moisturizing cream to produce a cosmetic cream with 1% of each bioactive.
EXAMPLE 14
Preparation of a CoQi0 /avocado oil/vitamin E body spray. Cremophor EL (4Og) is heated to around 600C until a clear liquid results. CoQio (4g), avocado oil (8g) and vitamin E (6g) are mixed and heated to around 600C until a clear liquid results. Cremophor EL and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to
600C and mixed until a single phase solution results. 2Og of the mixture is added to 500g of spring water and the mixture stirred vigorously until the complex disperses and a clear solution results. The solution containing 0.08% CoQio, 0.16% avocado oil and 0.12% vitamin E is filled into a spray bottle to produce an enriched body spray.
EXAMPLE 15
Preparation of a CoQi0 /Vitamin E capsule. Cremophor RH 40 (4Og) is heated to around 60°C until a clear liquid results. CoQi0 (5g) and vitamin E (5g) are mixed and heated to around 600C until a clear liquid results. Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated 60°C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 100 mg of water soluble CoQi0 and 100 mg of water soluble vitamin E results. Alternatively the complex can be encapsulated in a soft gelatine capsule.
EXAMPLE 16
Preparation of a CoQi0 /avocado oil capsule. Cremophor RH 40 (4Og) is heated to around 60°C until a clear liquid results. CoQi0 (5g) and avocado oil (5g) are mixed and heated to around 60 0C until a clear liquid results. Cremophor RH 40 and the bioactive mixture are combined in an appropriate ratio and the mixture reheated 600C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 100 mg of water soluble CoQi0 and 100 mg of water soluble avocado oil results. Alternatively the complex can be encapsulated in a soft gelatine capsule.
EXAMPLE 17
Preparation of a CoQi0 /avocado oil/vitamin E capsule. Cremophor RH 40 (6Og) is heated to around 600C until a clear liquid results. CoQi0 (5g), avocado oil (5g) and vitamin E (5g) are mixed and heated to around 6O0C until a clear liquid results.
Cremophor EL and the bioactive mixture are combined in an appropriate ratio and the mixture reheated to 6O0C and mixed until a single phase solution results. Ig of the mixture while warm is added to a "000" hard gelatine capsule and allowed to cool. A capsule containing 67 mg of water soluble CoQi0, 67 mg of water soluble avocado oil amd 67 mg of water soluble vitamin E results. Alternatively the complex can be encapsulated in a soft gelatine capsule.
Various embodiments of the present invention having been thus described in detail by way of example, it will be apparent to those skilled in the art that variations and modifications may be made without departing from the invention. The invention includes all such variations and modifications as fall within the scope of the appended claims.
Having thus described the present invention in detail, it will be obvious to those skilled in the art that various changes or modifications may be made without departing from the scope of the invention defined in the appended claims and described in the specification.
Claims
1. A method of preparing a stable solution including a lipophilic bioactive compound and water comprising the steps of:
providing a non-ionic surfactant;
preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio;
heating the mixture to a temperature necessary to obtain a clear melt; and
adding heated water to the mixture to form the stable solution.
2. A method of preparing a stable complex including a lipophilic bioactive compound comprising the steps of:
providing a non-ionic surfactant;
preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio;
heating the mixture to a temperature necessary to obtain a clear melt.
3. A method according to claim 1 or 2 wherein the lipophilic bioactive compound is selected from the group consisting of: ubiquinones, ubiquinols and sterols; amphotericin- B, nystatin, and candicidin antibiotics; anticancer drugs such as taxol and doxorubicin; anesthetics such as propafol; phytosterols, sterols, sterol esters; fish oil containing polyunsaturated fatty acids, omega 3 fatty acids, EPA, DHA; carotenoids, such as β- carotene, astaxanthin, canatxanthin, lycopene; squalenes; gamma-tocopherol; curcumin; lignans; lunastatin; leutin; aloe vera; essential oils such as tea tree, basil, eucalyptus, cedarwood, cypress, lemon, lavender, sage, lemongrass, evening primrose, chamomile, lavender, geranium, rose, neroli, ylang ylang, clary sage, palmarosa, carrot, basil; carrier oils such as sunflower, walnut, olive, sweet almond, apricot kernel, avocado, borage, caster, coconut, emu, grapeseed, jojaba, kukui, nut, olive, peanut, sesame, safflower, wheat germ; oleoresin; retinoic acid; adapalene; azelaic acid; asiatic acid; fatty acids; polyenoic fatty acids; and mixtures thereof.
4. A method according to claim 1 or 2 wherein the lipophilic bioactive compound is CoQio.
5. A method according to any one of claims 1-4 wherein the non-ionic surfactant is selected from the group consisting of polyoxyl 40 hydrogenated caster oil, polyoxyl 35 caster oil, macrogol 15 hydroxystearate, caprylocaproyl polyoxyglycerides,lauroyl polyoxyglycerides, stearoyl polyoxylglycerdes and d-α-tocopheryl polyethylene glycol succinate; and mixtures thereof.
6. A method according to any one of claims 1-5 wherein the non-ionic surfactant is selected from the group consisting of polyoxyl 40 hydrogenated caster oil and polyoxyl 35 caster oil; and mixtures thereof.
7. A method according to any one of claims 1-5 wherein the non-ionic surfactant is selected from the group consisting of macrogol 15 hydroxystearate and d-α-tocopheryl polyethylene glycol succinate; and mixtures thereof.
8. A method according to claim 1 or 2, wherein the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant is from about 1 :0.5 to about 1 :25.
9. A method according to claim 1 , wherein the mixture is heated to about 65°C.
10. Use of a non-ionic surfactant for preparing a water soluble lipophilic bioactive composition.
11. Use according to claim 10 wherein the lipophilic bioactive compound is selected from the group consisting of: ubiquinones, ubiquinols and sterols; amphotericin-B, nystatin, and candicidin antibiotics; anticancer drugs such as taxol and doxorubicin; anesthetics such as propafol; idebenone, phytosterols, sterols, sterol esters; fish oil containing polyunsaturated fatty acids, omega 3 fatty acids, EPA, DHA; carotenoids, such as β-carotene, astaxanthin, canatxanthin, lycopene; squalenes; gamma-tocopherol; curcumin; lignans; lunastatin; leutin; aloe vera; essential oils such as tea tree, basil, eucalyptus, cedarwood, cypress, lemon, lavender, sage, lemongrass, evening primrose, chamomile, lavender, geranium, rose, neroli, ylang ylang, clary sage, palmarosa, carrot, basil; carrier oils such as sunflower, walnut, olive, sweet almond, apricot kernel, avocado, borage, caster, coconut, emu, grapeseed, jojaba, kukui, nut, olive, peanut, sesame, safflower, wheat germ; oleoresin; retinoic acid; adapalene; azelaic acid; asiatic acid; fatty acids; polyenoic fatty acids; and mixtures thereof.
12. Use according to claim 10 or 11 wherein the lipophilic bioactive compound is CoQ10.
13. Use according to any one of claims 10 to 12 wherein the non-ionic surfactant is selected from the group consisting of polyoxyl 40 hydrogenated caster oil, polyoxyl 35 caster oil, macrogol 15 hydroxy stearate, caprylocaproyl polyoxyglycerides, huroyl polyoxyglycerides, stearoyl polyoxylglycerdes and d-α-tocopheryl polyethylene glycol succinate; and mixtures thereof.
14. Use according to any one of claims 10-12 wherein the non-ionic surfactant is selected from the group consisting of polyoxyl 40 hydrogenated caster oil and polyoxyl 35 caster oil; and mixtures thereof.
15. Use according to any one of claims 10-12 wherein the non-ionic surfactant is selected from the group consisting of macrogol 15 hydroxy stearate and d-α-tocopheryl polyethylene glycol succinate; and mixtures thereof.
16. A pharmaceutical water soluble composition comprising an effective amount of a lipophilic compound and a non-ionic surfactant.
17. A pharmaceutical composition according to claim 16 further comprising a pharmaceutically acceptable additive or vehicle selected from the group consisting of solvents, adjuvants, sweeteners, fillers, colourants, flavouring agents, lubricants, binders, moisturizing agents, preservatives and mixtures thereof.
18. A pharmaceutical composition according to claim 16, in a form suitable for topical, oral, parenteral, or inhaled administration and in a form suitable for patch and aerosol delivery.
19. A pharmaceutical composition according to claim 16, wherein the composition is lyophilized for topical application, oral delivery, or parenteral administration.
20. A cosmetic water soluble composition comprising an effective amount of a lipophilic compound and a non-ionic surfactant.
21. A cosmetic composition according to claim 20 further comprising a cosmetically acceptable additive or vehicle selected from the group consisting of solvents, adjuvants, sweeteners, fillers, colourants, flavouring agents, lubricants, binders, moisturizing agents, preservatives and mixtures thereof.
22. A hair care water soluble composition comprising an effective amount of a lipophilic compound and a non-ionic surfactant.
23. A hair care composition according to claim 22 further comprising a cosmetically acceptable additive or vehicle selected from the group consisting of solvents, adjuvants, sweeteners, fillers, colourants, flavouring agents, lubricants, binders, moisturizing agents, preservatives and mixtures thereof.
24. A food water soluble composition comprising an effective amount of a bioactive lipophilic compound and a non-ionic surfactant.
25. A food composition according to claim 24 further comprising a food acceptable additive or vehicle selected from the group consisting of solvents, adjuvants, sweeteners, fillers, colourants, flavouring agents, lubricants, binders, moisturizing agents, preservatives and mixtures thereof.
26. A composition according to claim 20, 22 or 24, in a form suitable for topical, oral, parenteral, or inhaled administration and in a form suitable for patch and aerosol delivery.
27. A method of the prophylaxis or treatment of a medical disorder associated with oxidative tissue damages or mitochondrial dysfunctions, said method comprising administering to a human or a warm-blooded animal in need of such prophylaxis or treatment a therapeutically effective amount of a water-soluble composition according to claim any one of claims 16-25.
28. A method according to claim 27, wherein the disorder is selected from the group consisting of heart diseases, ischemia/reperfusion tissue damages, neurodegenerative disorders and mitochondrial encephalomyolopaties.
28. Use of the pharmaceutical composition according to claim 16 or 17 for the treatment of an ailment in a human or warm blooded animal.
29. Use of the pharmaceutical composition according to claim 16 or 17 for the treatment of a fungal infection, wherein a macrolide polyene antibiotic is the bioactive lipophilic compound, in conjunction with a pharmaceutically acceptable diluent or carrier.
30. Use of the pharmaceutical composition according to claim 16 or 17 for the treatment of a cancer or neurogenerative diseases or cardiovascular diseases.
31. Use of the pharmaceutical composition according to claim 16 or 17 for the treatment of a condition associated with high cholesterol and high blood pressure.
32. A method of the prophylaxis or treatment of a condition associated with a deficiency in a lipophilic compound.
33. Use of cosmetic, hair care and food compositions according to claim 26 for the treatment of a condition in a human or warm blooded animal.
34. A method of preparing a stable complex including a lipophilic bioactive compound comprising the steps of:
providing a non-ionic surfactant;
preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio in a water-miscible organic solvent;
diluting the mixture with a predetermined amount of water; and
removing the organic solvent from the mixture and optionally an amount of water necessary to achieve a desired concentration of the water-soluble composition.
35. A method of preparing a single-phase solution comprising the steps of: pre-treating at least one non-ionic surfactant; pre-treating at least one lipophilic bioactive compound; preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio necessary to produce a single phase solution; and heating the mixture to a temperature necessary to obtain a clear melt and cooling to form the single-phase soluion.
36. The method of claim 35, wherein the heating and cooling of the combined mixture is repeated to form the single-phase solution.
37. The method of claim 35, wherein the lipophilic compound and non-ionic surfactant is agitated together to form the single-phase solution.
38. The method of claim 35, wherein the single-phase solution is added to water or other beverage.
39. The method of Claim 38 where the solution is filter sterilized, heat sterilized or pasteurized.
40. The method of claim 35, wherein the mixture is filled into a hard or soft gelatine capsule.
41. The method of claim 38, wherein the mixture is lyophilized for topical, oral or parenteral administration.
42 The method of claim 35, wherein the mixture is formulated into a compressed tablet, conventional capsule or IV formulation.
43. The method of claim 35, wherein the surfactant is melted to its melting point to form a liquid surfactant mixture and and the bioactive compound is melted to its melting point to form a liquid bioactive compound mixture.
44. The method of claim 35, wherein the liquid mixtures are combined, mixed and reelted until a single phase solution results.
45. The method of claim 35, wherein the lipophilic bioactive compound is selected from the group consisting of: ubiquinones, ubiquinols and sterols; amphotericin-B, nystatin, and candicidin antibiotics; anticancer drugs such as taxol and doxorubicin; anesthetics such as propafol; phytosterols, sterols, sterol esters; fish oil containing polyunsaturated fatty acids, omega 3 fatty acids, EPA, DHA; carotenoids, such as β- carotene, astaxanthin, canatxanthin, lycopene; squalenes; gamma-tocopherol; curcumin; lignans; lunastatin; leutin; aloe vera; essential oils, such as tea tree, basil, eucalyptus, cedarwood, cypress, lemon, lavender, sage, lemongrass, evening primrose, chamomile, lavender, geranium, rose, neroli, ylang ylang, clary sage, palmarosa, carrot, basil; carrier oils, such as sunflower, walnut, olive, sweet almond, apricot kernel, avocado, borage, caster, coconut, emu, grapeseed, jojaba, kukui, nut, olive, peanut, sesame, safflower, wheat germ; oleoresin; retinoic acid; adapalene; azelaic acid; asiatic acid; fatty acids; polyenoic fatty acids; and mixtures thereof.
46. The method of claim 42, including two or more lipophilic bioactive compounds.
47. The method of claim 42, wherien the lipophilic bioactive compound is CoQi0.
48. The method of claim 42, wherein the lipophilic bioactive compound is fish oil.
49. The method of claim 35, wherein the non-ionic surfactant contains polyethylene glycol (PEG).
40. The method of claim 44, wherein the non-ionic surfactant is selected from the group consisting of Cremophor RH 40™ (polyoxyl 40 hydrogenated castor oil), Cremophor EL™ (polyoxyl 35 castor oil), Cremophor ELP™ (polyoxyl 35 castor oil), and Solutol HS 15™ (macrogol 15 hydroxystearate), PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-60 castor oil, monostearate (and derivatives thereof), glyceryl laurate, glyceryl stearate, glyceryl oleate, glyceryl monooleate, glyceryl monolaurate, sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan stearate, nonyl phenols, octyl phenols, caprylocaproyl polyoxyglycerides, lauroyl polyoxyglycerides, stearoyl polyoxylglycerdes and d-α-tocopheryl polyethylene glycol succinate, or combinations thereof.
41. The method of claim 35, including two or more lipophilic bioactive compounds.
42 The method of claim 35, wherein the non- ionic surfactant is cremophor.
43. The method of claim 40, wherein the lipophilic bioactive compound is selected from vitamin E, vitamin A, vitamin K, and vitamin D, and prodrugs or derivatives thereof.
44. The method of claim 35, wherein the single-phase solution is formulated for cosmetic, pharmaceutical, nutritional, dietary or supplemental applications.
45. A single-phase composition comprising at least one non-ionic surfactant and at least one lipophilic bioactive compound prepared by the method of claim 1.
46. A single-phase solution comprising: at least one non-ionic surfactant, and at least one lipophilic bioactive compound, wherein the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant is from about 1 :0.5 to about 1 :25.
47. The single-phase solution of claim 46, wherein the lipophilic bioactive compound is selected from the group consisting of: ubiquinones, ubiquinols and sterols; amphotericin-B, nystatin, and candicidin antibiotics; anticancer drugs such as taxol and doxorubicin; anesthetics such as propafol; phytosterols, sterols, sterol esters; fish oil containing polyunsaturated fatty acids, omega 3 fatty acids, EPA, DHA; carotenoids, such as β-carotene, astaxanthin, canatxanthin, lycopene; squalenes; gamma-tocopherol; curcumin; lignans; lunastatin; leutin; aloe vera; essential oils, such as tea tree, basil, eucalyptus, cedarwood, cypress, lemon, lavender, sage, lemongrass, evening primrose, chamomile, lavender, geranium, rose, neroli, ylang ylang, clary sage, palmarosa, carrot, basil; carrier oils, such as sunflower, walnut, olive, sweet almond, apricot kernel, avocado, borage, caster, coconut, emu, grapeseed, jojaba, kukui, nut, olive, peanut, sesame, safflower, wheat germ; oleoresin; retinoic acid; adapalene; azelaic acid; asiatic acid; fatty acids; polyenoic fatty acids; and mixtures thereof.
48. The single-phase solution of claim 47, including two or more lipophilic bioactive compounds.
49. The single-phase solution of claim 47, wherien the lipophilic bioactive compound is CoQio.
50. The single-phase solution of claim 47, wherein the lipophilic bioactive compound is fish oil.
51. The single-phase solution of claim 47, wherein the non-ionic surfactant contains polyethylene glycol (PEG).
52. The single-phase solution of claim 51, wherein the non-ionic surfactant is selected from the group consisting of Cremophor RH 40™ (polyoxyl 40 hydrogenated castor oil), Cremophor EL™ (polyoxyl 35 castor oil), Cremophor ELP™ (polyoxyl 35 castor oil), and Solutol HS 15™ (macrogol 15 hydroxystearate), PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-60 castor oil, monostearate (and derivatives thereof), glyceryl laurate, glyceryl stearate, glyceryl oleate, glyceryl monooleate, glyceryl monolaurate, sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan stearate, nonyl phenols, octyl phenols, caprylocaproyl polyoxyglycerides, lauroyl polyoxyglycerides, stearoyl polyoxylglycerdes and d-α-tocopheryl polyethylene glycol succinate, or combinations thereof.
53. The single-phase solution of claim 46, including two or more lipophilic bioactive compounds.
54. The single-phase solution of claim 46, wherein the non-ionic surfactant is cremophor.
55. The single-phase solution of claim 46, wherein the bioactive compound is at least 15% of the single-phase solution.
56. The single-phase solution of claim 46, wherein the single-phase solution is added to water or other beverage.
57. The single-phase solution of claim 46, wherein the mixture is filled into a hard or soft gelatine capsule.
58. The single-phase solution of claim 57, wherein the lipophilic bioactive compound is selected from vitamin E, vitamin A, vitamin K, and vitamin D, and prodrugs or derivatives thereof.
59. The single-phase solution of claim 46 formulated for cosmetic, pharmaceutical, nutritional, dietary or supplemental applications.
60. A method of preparing a stable complex including a lipophilic bioactive compound comprising the steps of: providing at least one non-ionic surfactant; providing at least one lipophilic bioactive compound; preparing a mixture of the lipophilic bioactive compound and the non-ionic surfactant in a predetermined molar ratio in a water-mi scible organic solvent wherein the molar ratio of the bioactive lipophilic compound and the non-ionic surfactant is from about 1 :0.5 to about 1 :25; diluting the mixture with a predetermined amount of water; and removing the organic solvent from the mixture and optionally an amount of water necessary to achieve a desired concentration of the water-soluble composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89110507P | 2007-02-22 | 2007-02-22 | |
US60/891,105 | 2007-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008101344A1 true WO2008101344A1 (en) | 2008-08-28 |
Family
ID=39709592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2008/000336 WO2008101344A1 (en) | 2007-02-22 | 2008-02-22 | Soluble bioactive lipophilic compounds compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008101344A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008059201A1 (en) * | 2008-11-27 | 2010-06-02 | GÖPFERICH, Achim, Prof. Dr. | In situ precipitating drug solutions |
CN103462887A (en) * | 2013-08-09 | 2013-12-25 | 张蕊 | Vitamin K1 injection and preparation method thereof |
US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
WO2014025672A1 (en) * | 2012-08-04 | 2014-02-13 | Eric Hauser Kuhrts | Water-soluble lipophilic natural compound formulations |
EP2488022A4 (en) * | 2009-10-16 | 2014-02-19 | Glaxosmithkline Llc | Compositions |
EP2471545A4 (en) * | 2009-05-11 | 2014-04-02 | Herrero Maria Pilar Mateo | Microencapsulated composition based on saponified olea europaea, use thereof and production method of same |
US8795634B2 (en) | 2008-09-12 | 2014-08-05 | Critical Pharmaceuticals Limited | Absorption of therapeutic agents across mucosal membranes or the skin |
JP2016505579A (en) * | 2012-12-19 | 2016-02-25 | アクアノヴァ アクチエンゲゼルシャフト | Curcumin solubilized product |
WO2016071434A1 (en) * | 2014-11-05 | 2016-05-12 | Abbott Laboratories Gmbh | Processes for producing compositions with improved safety profile comprising pancreatin and compositions suitable for pharmaceutical use |
US9750705B2 (en) | 2012-08-31 | 2017-09-05 | The Regents Of The University Of California | Agents useful for treating obesity, diabetes and related disorders |
US9889098B2 (en) | 2009-10-22 | 2018-02-13 | Vizuri Health Sciences Llc | Methods of making and using compositions comprising flavonoids |
WO2019148282A1 (en) | 2018-02-01 | 2019-08-08 | The Royal Institution For The Advancement Of Learning/Mcgill University | Formulations for improving the delivery of hydrophobic agents |
CN110200910A (en) * | 2019-06-17 | 2019-09-06 | 宁波海奇合昇环能科技有限公司 | A kind of preparation method of the transparent aqueous dispersions of Co-Q10 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0179583A1 (en) * | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
CA2313024A1 (en) * | 1997-12-10 | 1999-06-17 | Severson, Mary L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
US6045826A (en) * | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
WO2002056709A1 (en) * | 2001-01-17 | 2002-07-25 | R.P. Scherer Technologies, Inc. | Ingestible compositions containing an odoriferous oil |
CA2442151A1 (en) * | 2001-05-09 | 2002-11-14 | Kaneka Corporation | Stable solution of reduced coenzyme q |
EP1464341A1 (en) * | 2003-04-03 | 2004-10-06 | Visufarma S.R.L. | Ubiquinone-containing water-soluble formulation for ophthalmic use |
WO2005079758A1 (en) * | 2004-02-13 | 2005-09-01 | Bioavailability, Inc. | A microemulsion preparation of high concentration propofol for anesthetic uses |
WO2006080903A2 (en) * | 2004-11-16 | 2006-08-03 | Bioavailability, Inc. | High concentration self-microemulsifying coenzyme q10 preparations for nutritional use |
-
2008
- 2008-02-22 WO PCT/CA2008/000336 patent/WO2008101344A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0179583A1 (en) * | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
CA2313024A1 (en) * | 1997-12-10 | 1999-06-17 | Severson, Mary L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
US6045826A (en) * | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
WO2002056709A1 (en) * | 2001-01-17 | 2002-07-25 | R.P. Scherer Technologies, Inc. | Ingestible compositions containing an odoriferous oil |
CA2442151A1 (en) * | 2001-05-09 | 2002-11-14 | Kaneka Corporation | Stable solution of reduced coenzyme q |
EP1464341A1 (en) * | 2003-04-03 | 2004-10-06 | Visufarma S.R.L. | Ubiquinone-containing water-soluble formulation for ophthalmic use |
WO2005079758A1 (en) * | 2004-02-13 | 2005-09-01 | Bioavailability, Inc. | A microemulsion preparation of high concentration propofol for anesthetic uses |
WO2006080903A2 (en) * | 2004-11-16 | 2006-08-03 | Bioavailability, Inc. | High concentration self-microemulsifying coenzyme q10 preparations for nutritional use |
Non-Patent Citations (1)
Title |
---|
NAZZAL S. ET AL.: "Analysis of ubidecarenone (CoQ10) aqueous samples using reversed phase liquid chromatography", PHARMAZIE, vol. 56, no. 5, May 2001 (2001-05-01), pages 394 - 396 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8795634B2 (en) | 2008-09-12 | 2014-08-05 | Critical Pharmaceuticals Limited | Absorption of therapeutic agents across mucosal membranes or the skin |
US9700509B2 (en) | 2008-11-27 | 2017-07-11 | Universität Regensburg | Solutions of lipophilic substances, especially medicinal solutions |
DE102008059201A1 (en) * | 2008-11-27 | 2010-06-02 | GÖPFERICH, Achim, Prof. Dr. | In situ precipitating drug solutions |
EP2471545A4 (en) * | 2009-05-11 | 2014-04-02 | Herrero Maria Pilar Mateo | Microencapsulated composition based on saponified olea europaea, use thereof and production method of same |
US10668038B2 (en) | 2009-10-16 | 2020-06-02 | Mochida Pharmaceutical Co., Ltd. | Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed |
US9717703B2 (en) | 2009-10-16 | 2017-08-01 | Glaxosmithkline Llc | Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed |
EP2488022A4 (en) * | 2009-10-16 | 2014-02-19 | Glaxosmithkline Llc | Compositions |
US9730953B2 (en) | 2009-10-22 | 2017-08-15 | Vizuri Health Sciences Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound |
US11135177B2 (en) | 2009-10-22 | 2021-10-05 | Vizuri Health Sciences Consumer Healthcare, Inc. | Methods of making and using compositions comprising flavonoids |
US11491226B2 (en) | 2009-10-22 | 2022-11-08 | Technology Investments Lc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound |
US9889098B2 (en) | 2009-10-22 | 2018-02-13 | Vizuri Health Sciences Llc | Methods of making and using compositions comprising flavonoids |
US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
US9731015B2 (en) | 2012-08-04 | 2017-08-15 | Eric Hauser Kuhrts | Water-soluble lipophilic natural compound formulations |
WO2014025672A1 (en) * | 2012-08-04 | 2014-02-13 | Eric Hauser Kuhrts | Water-soluble lipophilic natural compound formulations |
US9750705B2 (en) | 2012-08-31 | 2017-09-05 | The Regents Of The University Of California | Agents useful for treating obesity, diabetes and related disorders |
US11311483B2 (en) | 2012-12-19 | 2022-04-26 | Aquanova Ag | Curcumin solubilisate |
JP2016505579A (en) * | 2012-12-19 | 2016-02-25 | アクアノヴァ アクチエンゲゼルシャフト | Curcumin solubilized product |
CN103462887A (en) * | 2013-08-09 | 2013-12-25 | 张蕊 | Vitamin K1 injection and preparation method thereof |
CN107073084A (en) * | 2014-11-05 | 2017-08-18 | 雅培制药股份有限公司 | Method for producing the composition with lipase active and the composition suitable for medicinal usage with improved security feature |
RU2712142C2 (en) * | 2014-11-05 | 2020-01-24 | Эбботт Лабораторис Гмбх | Methods of producing compositions with improved safety profile containing pancreatin, and compositions suitable for pharmaceutical use |
WO2016071434A1 (en) * | 2014-11-05 | 2016-05-12 | Abbott Laboratories Gmbh | Processes for producing compositions with improved safety profile comprising pancreatin and compositions suitable for pharmaceutical use |
WO2019148282A1 (en) | 2018-02-01 | 2019-08-08 | The Royal Institution For The Advancement Of Learning/Mcgill University | Formulations for improving the delivery of hydrophobic agents |
CN110200910A (en) * | 2019-06-17 | 2019-09-06 | 宁波海奇合昇环能科技有限公司 | A kind of preparation method of the transparent aqueous dispersions of Co-Q10 |
CN110200910B (en) * | 2019-06-17 | 2022-04-19 | 北京中超海奇科技有限公司 | Preparation method of coenzyme Q10 transparent aqueous dispersion |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008101344A1 (en) | Soluble bioactive lipophilic compounds compositions | |
Ashaolu | Nanoemulsions for health, food, and cosmetics: a review | |
Katouzian et al. | Formulation and application of a new generation of lipid nano-carriers for the food bioactive ingredients | |
KR101430767B1 (en) | Compositions and methods for making and using nanoemulsions | |
JP2020502040A (en) | Method for selectively extracting cannabinoids from plant sources | |
KR101061679B1 (en) | Water-soluble composition containing coenzyme # 10 | |
BRPI1002486A2 (en) | stable topical composition and process for obtaining stable topical composition | |
WO2005105040A2 (en) | Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications | |
AU2011213557B2 (en) | Carrier comprising non-neutralised tocopheryl phosphate | |
TWI531318B (en) | Microemulsion preconcentrates and microemulsions, and preparation processes of the same | |
JP3833648B2 (en) | Water-soluble composition containing coenzyme Q10 | |
WO2012129072A1 (en) | Solid particulate compositions comprising coenzyme q10 | |
JP2022509463A (en) | A product composed of water-soluble particles of non-curcuminoid and water-soluble particles of curcuminoid. | |
WO2008007728A1 (en) | Oral preparation in the form enclosed in lipid membrane structure, and fatigue-ameliorating agent comprising coenzyme a as active ingredient | |
Wu et al. | Nutraceutical delivery systems to improve the bioaccessibility and bioavailability of lycopene: A review | |
CA3128653A1 (en) | Nanoemulsion compositions comprising saponins for increasing bioavailability | |
WO2022232897A1 (en) | Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof | |
WO2020208642A1 (en) | Formulations for encapsulation and bioavailability improvement of bioactive compounds based on natural plant based materials | |
JP6622950B1 (en) | Compositions for preparing microemulsions, microemulsions, methods for their production and use of microemulsions | |
KR102102098B1 (en) | A composition of emulsion preconcentrate comprising protopaxadiol | |
JP2006306879A (en) | Method for producing water-soluble composition containing coenzyme q10 | |
Attama et al. | Applications of nanoemulsions as drug delivery vehicle for phytoconstituents | |
JP2021011467A (en) | Microemulsion and use of microemulsion | |
KR20100016290A (en) | Emulsion preconcentrates and micellar formulations containing wood resins | |
D’Souza et al. | Potential of oils in development of nanostructured lipid carriers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08714658 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08714658 Country of ref document: EP Kind code of ref document: A1 |